bit.bio raises $103 million in first close of Series B financing
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
List view / Grid view
The funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM.
Repositive, the company that created the world’s largest portal for accessing human genomic research data, has closed a Series A funding round of £2.5 million.
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Amadeus Capital Partners has made an early-stage investment in Healx that seeks new uses for existing drugs in the fight against rare diseases...